• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Formulation and stabilization of Francisella tularensis live vaccine strain.弗朗西斯氏土拉弗氏菌活疫苗株的配方与稳定化。
J Pharm Sci. 2011 Aug;100(8):3076-3087. doi: 10.1002/jps.22563. Epub 2011 Apr 13.
2
Increased encapsulation and virulence of Francisella tularensis live vaccine strain (LVS) by subculturing on synthetic medium.通过在合成培养基上进行传代培养增加土拉弗朗西斯菌活疫苗株(LVS)的包囊化和毒力。
Vaccine. 1994 Jul;12(9):773-5. doi: 10.1016/0264-410x(94)90284-4.
3
Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain.土拉热弗朗西斯菌活疫苗株中减毒嘌呤营养缺陷型菌株的构建与鉴定
Infect Immun. 2006 Aug;74(8):4452-61. doi: 10.1128/IAI.00666-06.
4
Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines.口服、减毒活伤寒沙门氏菌 Typhi 疫苗的室温稳定化。
Vaccine. 2011 Mar 24;29(15):2761-71. doi: 10.1016/j.vaccine.2011.01.093. Epub 2011 Feb 5.
5
Francisella tularensis Live Vaccine Strain deficient in capB and overexpressing the fusion protein of IglA, IglB, and IglC from the bfr promoter induces improved protection against F. tularensis respiratory challenge.缺失capB基因且从bfr启动子过表达IglA、IglB和IglC融合蛋白的土拉弗朗西斯菌活疫苗株可诱导对土拉弗朗西斯菌呼吸道攻击的更好保护。
Vaccine. 2016 Sep 22;34(41):4969-4978. doi: 10.1016/j.vaccine.2016.08.041. Epub 2016 Aug 28.
6
A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.一株编码一种假定荚膜生物合成蛋白的 capB 缺失的活疫苗弗朗西斯氏菌(LVS)突变体比 LVS 显著减毒,但能诱导小鼠对弗朗西斯氏菌挑战产生强烈的保护性免疫。
Infect Immun. 2010 Oct;78(10):4341-55. doi: 10.1128/IAI.00192-10. Epub 2010 Jul 19.
7
Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS.土拉热弗朗西斯菌LVS O抗原缺陷突变株的减毒作用及保护效力
Microbiology (Reading). 2007 Sep;153(Pt 9):3141-3153. doi: 10.1099/mic.0.2007/006460-0.
8
An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes.一种改良的土拉弗朗西斯菌活疫苗株(LVS),当采用不同免疫途径以递增剂量给兔子接种时,耐受性良好且具有高度免疫原性。
Vaccine. 2008 Mar 25;26(14):1773-85. doi: 10.1016/j.vaccine.2008.01.005. Epub 2008 Jan 29.
9
Efficacy of the live attenuated Francisella tularensis vaccine (LVS) in a murine model of disease.减毒活土拉弗朗西斯菌疫苗(LVS)在小鼠疾病模型中的疗效。
Vaccine. 2005 Apr 8;23(20):2680-6. doi: 10.1016/j.vaccine.2004.03.071.
10
Genetic engineering of Francisella tularensis LVS for use as a novel live vaccine platform against Pseudomonas aeruginosa infections.对土拉热弗朗西斯菌活疫苗株进行基因工程改造,用作抗铜绿假单胞菌感染的新型活疫苗平台。
Bioengineered. 2015;6(2):82-8. doi: 10.1080/21655979.2015.1011033.

引用本文的文献

1
Modern Development and Production of a New Live Attenuated Bacterial Vaccine, SCHU S4 , to Prevent Tularemia.新型减毒活细菌疫苗 SCHU S4 预防兔热病的现代研发与生产
Pathogens. 2021 Jun 23;10(7):795. doi: 10.3390/pathogens10070795.
2
Pharmaceutical protein solids: Drying technology, solid-state characterization and stability.药物蛋白固体:干燥技术、固态特性分析和稳定性。
Adv Drug Deliv Rev. 2021 May;172:211-233. doi: 10.1016/j.addr.2021.02.016. Epub 2021 Mar 8.
3
Trehalose and bacterial virulence.海藻糖与细菌毒力。
Virulence. 2020 Dec;11(1):1192-1202. doi: 10.1080/21505594.2020.1809326.
4
Detection of and in Tissues of Wild-living Animals and in Ticks of North-west Poland.波兰西北部野生动物组织及蜱虫中[具体物质]的检测
Pol J Microbiol. 2018;67(4):529-534. doi: 10.21307/pjm-2018-059.
5
Osmolytes in vaccine production, flocculation and storage: a critical review.疫苗生产、絮凝和储存中的渗透剂:批判性评价。
Hum Vaccin Immunother. 2019;15(2):514-525. doi: 10.1080/21645515.2018.1526585. Epub 2018 Oct 12.
6
A stable live bacterial vaccine.一种稳定的活细菌疫苗。
Eur J Pharm Biopharm. 2016 Jun;103:109-117. doi: 10.1016/j.ejpb.2016.03.027. Epub 2016 Mar 25.
7
Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors.克服基因传递障碍:非病毒载体的生理学考量
Trends Biotechnol. 2016 Feb;34(2):91-105. doi: 10.1016/j.tibtech.2015.11.004. Epub 2015 Dec 23.
8
Live attenuated tularemia vaccines: recent developments and future goals.减毒活兔热病疫苗:近期进展与未来目标
Vaccine. 2013 Aug 2;31(35):3485-91. doi: 10.1016/j.vaccine.2013.05.096. Epub 2013 Jun 10.
9
Spray-dried chitosan microparticles for cellular delivery of an antigenic protein: physico-chemical properties and cellular uptake by dendritic cells and macrophages.喷雾干燥壳聚糖微球用于抗原蛋白的细胞递送:物理化学性质及树突状细胞和巨噬细胞的摄取。
Pharm Res. 2013 Jun;30(6):1677-97. doi: 10.1007/s11095-013-1014-7. Epub 2013 Mar 13.

本文引用的文献

1
Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines.口服、减毒活伤寒沙门氏菌 Typhi 疫苗的室温稳定化。
Vaccine. 2011 Mar 24;29(15):2761-71. doi: 10.1016/j.vaccine.2011.01.093. Epub 2011 Feb 5.
2
Heat-stable measles vaccine produced by spray drying.喷雾干燥法生产稳定性好的麻疹疫苗。
Vaccine. 2010 Feb 3;28(5):1275-84. doi: 10.1016/j.vaccine.2009.11.024. Epub 2009 Nov 25.
3
Effect of dehydrated storage on the survival of Francisella tularensis in infant formula.脱水储存对婴儿配方奶粉中土拉弗朗西斯菌存活的影响。
Food Microbiol. 2009 Dec;26(8):932-5. doi: 10.1016/j.fm.2009.06.005. Epub 2009 Jun 12.
4
Safety, reactogenicity and immunogenicity of Francisella tularensis live vaccine strain in humans.土拉热弗朗西斯菌活疫苗株在人体中的安全性、反应原性和免疫原性。
Vaccine. 2009 Aug 6;27(36):4905-11. doi: 10.1016/j.vaccine.2009.06.036. Epub 2009 Jun 28.
5
Quantifying changes in the high-frequency dynamics of mixtures by dielectri spectroscopy.通过介电谱量化混合物高频动力学的变化。
J Phys Chem B. 2008 Dec 18;112(50):15980-90. doi: 10.1021/jp8034314.
6
Towards development of stable formulations of a live attenuated bacterial vaccine: a preformulation study facilitated by a biophysical approach.迈向减毒活细菌疫苗稳定制剂的研发:一项由生物物理方法推动的处方前研究
Hum Vaccin. 2009 May;5(5):322-31. doi: 10.4161/hv.5.5.7559. Epub 2009 May 8.
7
Freeze-drying of proteins in glass solids formed by basic amino acids and dicarboxylic acids.在由碱性氨基酸和二羧酸形成的玻璃状固体中对蛋白质进行冷冻干燥。
Chem Pharm Bull (Tokyo). 2009 Jan;57(1):43-8. doi: 10.1248/cpb.57.43.
8
Immunization by a bacterial aerosol.通过细菌气溶胶进行免疫接种。
Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4656-60. doi: 10.1073/pnas.0800043105. Epub 2008 Mar 14.
9
Development of stable influenza vaccine powder formulations: challenges and possibilities.稳定流感疫苗粉末制剂的研发:挑战与可能性
Pharm Res. 2008 Jun;25(6):1256-73. doi: 10.1007/s11095-008-9559-6.
10
Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying.利用糖玻璃技术合理设计流感亚单位疫苗粉末:防止血凝素在冷冻和冻干过程中的构象变化。
Vaccine. 2007 Aug 29;25(35):6447-57. doi: 10.1016/j.vaccine.2007.06.054. Epub 2007 Jul 16.

弗朗西斯氏土拉弗氏菌活疫苗株的配方与稳定化。

Formulation and stabilization of Francisella tularensis live vaccine strain.

机构信息

Aridis Pharmaceuticals, San Jose, California 95138.

Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201.

出版信息

J Pharm Sci. 2011 Aug;100(8):3076-3087. doi: 10.1002/jps.22563. Epub 2011 Apr 13.

DOI:10.1002/jps.22563
PMID:21491457
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3356159/
Abstract

Francisella tularensis live vaccine strain (F. tularensis LVS), a promising vaccine candidate for protection against F. tularensis exposure, is a particularly thermolabile vaccine and difficult to stabilize sufficiently for storage under refrigerated conditions. Our preliminary data show that F. tularensis LVS can be stabilized in the dried state using foam drying, a modified freeze drying method, with sugar-based formulations. The process was conducted under mild drying conditions, which resulted in a good titer retention following processing. The inclusion of osmolytes in the growth media resulted in an acceleration of growth kinetics, although no change in osmotolerance was observed. The optimized F. tularensis formulation, which contained trehalose, gelatin, and Pluronic F68 demonstrated stability for approximately 1.5 weeks at 37°C (i.e., time required for the vaccine to decrease in potency by 1 log(10) colony forming unit) and for 12 weeks at 25°C. At refrigerator storage condition (4°C), stabilized F. tularensis LVS vaccine exhibited no activity loss for at least 12 weeks. This stabilization method utilizes conventional freeze dryers and pharmaceutically approved stabilizers, and thus can be readily implemented at many manufacturing sites for large-scale production of stabilized vaccines. The improved heat stability of the F. tularensis LVS could mitigate risks of vaccine potency loss during long-term storage, shipping, and distribution.

摘要

弗氏耶尔森菌活疫苗株(F. tularensis LVS)是一种有前途的针对弗氏耶尔森菌暴露的疫苗候选物,它是一种特别不稳定的疫苗,难以充分稳定以在冷藏条件下储存。我们的初步数据表明,弗氏耶尔森菌 LVS 可以使用泡沫干燥(一种改良的冷冻干燥方法)在干燥状态下稳定下来,使用基于糖的配方。该过程在温和的干燥条件下进行,结果在加工后保持了良好的效价。在生长培养基中添加渗透剂会加速生长动力学,但没有观察到耐渗透压变化。优化的弗氏耶尔森菌配方含有海藻糖、明胶和泊洛沙姆 F68,在 37°C 下稳定约 1.5 周(即疫苗效力降低 1 对数(10)菌落形成单位所需的时间),在 25°C 下稳定 12 周。在冰箱储存条件(4°C)下,稳定的弗氏耶尔森菌 LVS 疫苗至少在 12 周内没有活性损失。这种稳定化方法利用了常规的冷冻干燥器和经批准的药物稳定剂,因此可以在许多制造现场轻松实施,以大规模生产稳定的疫苗。弗氏耶尔森菌 LVS 的热稳定性提高可以降低疫苗在长期储存、运输和分发过程中效力损失的风险。